





APR 23 2004

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)  
**Sheet 3 of 3**

Sheet 2 of 3

Assistant Commissioner for Patents, Alexandria, VA 22313-1450.  
PTO/SB/08A (08-00)  
100-00551-0001

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use 10-29-71  
Endorsement Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPT. OF COMMERCE  
Filing of information unless it displays a valid OMB control number.

<b>Application Number</b>	10/720,323
<b>Filing Date</b>	November 24, 2003
<b>First Named Inventor</b>	Jill Giles-Komar
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	CEN 249 CIPNP

**U.S. PATENT DOCUMENTS**

**FOREIGN PATENT DOCUMENTS**

Examiner Mohsen Haddad Date Considered 1/27/06  
IN-1000. Draw line through citation if not in conformance and not

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**\*EXAMINER: Initial if reference considered.** **Considered.** **Include copy of this form with next communication to applicant.**

**1** Unique citation designation number. **2** See attached Kinds of U.S. Patent Documents. **3** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **4** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **5** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **6** Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



Substitute for form T449APTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)  
**Sheet 3 of 3**

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
In a collection of information unless it displays a valid OMB control number.

<b>Application Number</b>	10/720,323
<b>Filing Date</b>	November 24, 2003
<b>First Named Inventor</b>	Jill Giles-Komar
<b>Group Art Unit</b>	1644
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	CEN 249 CIPNP

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)  
**Sheet 3 of 3**

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials*	Cite No.*	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
MH		TAM et al, "Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates equivalent affinity and functional blockade of glycoprotein lib/Ilib and $\alpha_5\beta_1$ integrins," vol. 98, No. 11, 09-15-1998, pages 1098-1091, USA.		
MH		TRIKHA et al, "A potential new application for a cardiovascular drug: Role for ReoPro (Abciximab), an inhibitor of GBIIB/IIA and alphaVbeta3 integrins, as an anti-cancer agent," Proceedings of the American Association for Cancer Research, vol. 41, March 2000, page 577, USA.		
MH		SUZUKI et al, "cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors," Cell Biology, November 1986, pages 8614-8618, vol. 83, Proc. National Academy Science, USA.		
MH		LEHMANN ET AL, "A monoclonal antibody inhibits adhesion to fibronectin and bitrionectin of a colon carcinoma cell line and recognizes the integrins $\alpha_5\beta_1$ , $\alpha_5\beta_3$ , $\alpha_5\beta_6$ , $\alpha_6\beta_1$ ," Cancer Research, 1994, pages 2102-2107, Vol. 54, USA.		
MH		GUNTHER CASTL, THOMAS HERMANN, MICHAEL STEURER, JORG ZIMJA, EBERHARD GUNSIUS, CLEMENS UNGER, AND ANDREA KRAFT, "Angiogenesis as a target for tumor treatment," Oncology, 1997, 177-84, Vol. 54.		
MH		BRIAN P. ELICEIRI AND DAVID A. CHERESH, "The role of alpha-v integrins during angiogenesis: insights into potential mechanisms of action and clinical development," The Journal of Clinical Investigation, May 1999, 1227-30, vol. 103, no. 9.		
MH		MARTIN FRIEDLANDER, PETER C. BROOKS, ROBERT W. SHAFFER, CHRISTINE M. KINCAID, JUDITH A. VARNER, AND DAVID A. CHERESH, "DEFINITION OF TWO ANGIOGENIC PATHWAYS BY DISTINCT ALPHA-V INTEGRINS," Science, Dec. 1, 1995, 1500-2, vol. 270.		
MH		LISA D. TAYLOR, CONDIE E. CARMACK, DENNIS HUSZAR, KAY M. HIGGINS, ROSHANAK MASHAYEKH, GETACHEW SEQUAR, STEPHEN R. SCHRAMM, CHIUNG-CHI KUO, SUSAN L. O'DONNELL, ROBERT M. KAY, OLIVE S. WOODHOUSE, AND NILS LONBERG, "Human Immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," International Immunology, 1994; 579-91, vol. 6 no. 4, Oxford University Press.		
MH		NILS LONBERG, LISA D. TAYLOR, FIONA A. HARDING, MARY TROUNSTINE, KAY M. HIGGINS, STEPHEN R. SCHRAMM, CHIUNG-CHI KUO, ROSHANAK MASHAYEKH, KATHRYN WYMORE, JAMES G. MCCABE, DONNA MUNOZ-O'REGAN, SUSAN L. O'DONNELL, ELIZABETH S. G. LAPACHET, TASH BENGOCHEA, DIANNE M. FISHWILD, CONDIE E. CARMACK, ROBERT M. KAY AND DENNIS HUSZAR, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," Nature, April 28, 1994, 856-9, vol. 368.		
MH		MICHAEL NEUBERGER, "Generating high-affinity human Mabs in mice," Nature Biotechnology, July 1996, 826, vol. 14.		
MH		DIANNE M. FISHWILD, SUSAN L. O'DONNELL, TASH BENGOCHEA, DEBRA V. HUDSON, FIONA HARDING, SUSAN L. BERNHARD, DEBBIE JONES, ROBERT M. KAY, KAY M. HIGGINS, STEPHEN R. SCHRAMM, AND NILS LONBERG, "High-affinity human IgG-kappa monoclonal antibodies from a novel strain of minilocus transgenic mice," Nature Biotechnology, July 1996, 845-51, vol. 14.		
MH		ELIZABETH A. WAYNER, ROBERT A. ORLANDO AND DAVID A. CHERESH, "Integrins alpha v beta 3 and alpha v beta 5. Contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface," J. Cell Biology, May 1991, 918-29, vol. 113, no. 4.		
MH		JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESCA MITJANS, SIMON L. GOODMAN AND IAN R. HART, "Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin," J. of Cell Science, 1995, 1227-38, vol. 108.		
MH		DAVID A. CHERESH AND ROBERT C. SPIRO, "Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor," J. of Biological Chemistry, Dec. 25 1987, 17703-11, vol. 262 no. 38.		
MH		HANS KEMPERMAN, YVONNE M. WIJNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells: Adhesion to Fibronectin is Mediated Solely by Small Amounts of alpha v beta 6, and alpha v beta 5 is Codistributed with Actin Fibers," Experimental Cell Research, 1997, 156-64, vol. 234.		
		MAXIME LEHMANN, CHANTAL BABENANDRASANA, RICHARD TAMURA, JEAN-CLAUDE LISSITZKY, VITO QUARANTA, JACQUES PICHON, AND JACQUES MARVALDI, "A Monoclonal Antibody Inhibits Adhesion to Fibronectin and Vitronectin of a Colon Carcinoma Cell Line and Recognizes the Integrins alpha v beta 3, alpha v beta 5, and alpha v beta 6," Cancer Research, Apr 15 1994, 2102-07, vol. 54.		

FORM PTO 1449 (modified)

ATTY DOCKET NO.  
2002\_1351


SERIAL NO.

10/270,323

JUL 12 2004

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)APPLICANT  
Yukio TOYODA et al.GROUP  
1641

Date Submitted to PTO: July 12, 2004



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
m+t	AJ	0 260 829	3/1988	EP			
m+t	AK	0 834 557	4/1998	EP			
	AL						
	AM						
	AN						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

m+t	AO	J. Orihara, "Sensitizing Capacity, Cross-Reactivity and Antigenic Determinants of Bisphenol A", The Journal of Stomatological Society, Vol. 59, No. 2, June 1992, pp. 439-455. English Abstract only.
m+t	AP	M. Castillo et al., "Analysis of Industrial Effluents to Determine Endocrine-Disrupting Chemicals", Trends in Analytical Chemistry, Vol. 16, No. 10, November 12, 1997, pp. 574- 583.
m+t	AQ	J. Gascon et al., "Detection of Endocrine-Disrupting Pesticides by Enzyme-Linked Immunosorbent Assay (ELISA): Application to Atrazine", Trends in Analytical Chemistry, Vol. 16, No. 10, 1997, pp. 554-562.

EXAMINER Maher Haddad

DATE CONSIDERED 1/27/06



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

<p><b>SUBMISSION UNDER MPEP 609 D</b></p> <p>Page 1 of 1</p>	<b>Application Number</b>	10/720,323
	<b>Filing Date</b>	NOVEMBER 24, 2003
	<b>First Named Inventor</b>	JILL GILES-KOMAR
	<b>Group Art Unit</b>	1644
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	CEN249CIPNP

U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner 's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>mjt</i>		MITJANS et al, "In Vivo Therapy of Malignant Melanoma by Means of Antagonists of $\alpha v$ Integrins," Int. J. Cancer, 2000, pp 718-723, Vol. 87, Wiley-Liss, Inc., Spain.	
<i>mjl</i>		MITJANS et al, "An anti- $\alpha v$ -integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," Journal of Cell Science, 1995, pp 2825-2838, Vol. 108, The Company of Biologists Limited, Great Britain.	
<i>mjt</i>		CASEL et al, "RGD Peptides and Monoclonal Antibodies, Antagonists of $\alpha v$ -Integrin, Enter the Cells by Independent Endocytic Pathways," Laboratory Investigation, 2001, pp 1615-1626, Vol. 81, No. 12, The United States and Canadian Academy of Pathology, Inc., USA.	

Examiner Signature	Maher Haddad	Date Considered	1/27/06
--------------------	--------------	-----------------	---------